Award
National Institute of Allergy and Infectious Diseases 5R01AI160269-05
Novel cyclic boronate Penicillin Binding Protein Inhibitors to eliminate the threat posed by β-lactamases and enable a future treatment option for carbapenem-resistant Enterobacterales infections
Recipient
National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH)
Award Amount
$1,220,775.00
Ceiling
$1,220,775.00
Awarded
May 21, 2025
Identifier
5R01AI160269-05
NIH awarded a grant to develop novel cyclic boronate Penicillin Binding Protein inhibitors targeting carbapenem-resistant Enterobacterales infections, focusing on microbiological activity, pharmacokinetics, and structure-guided design.
Description
This is a NIH grant project focusing on developing cyclic boronate PBP inhibitors to combat carbapenem-resistant Enterobacterales. The project involves microbiological activity, pharmacokinetics, and structure-guided design to improve antibacterial activity.